tiletamine hydrochloride has been researched along with fludarabine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Higashihara, M; Horie, R; Motoji, T; Okamura, T; Shoda, M; Taira, M; Umezawa, K; Utsunomiya, A; Watanabe, M; Watanabe, T | 1 |
1 other study(ies) available for tiletamine hydrochloride and fludarabine
| Article | Year |
|---|---|
DHMEQ, a new NF-kappaB inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Benzamides; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspases; CD40 Antigens; Cell Line, Tumor; Cell Survival; Cyclohexanones; Down-Regulation; Drug Synergism; Female; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine | 2006 |